RANCHO CORDOVA, Calif., Feb. 6 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury, today reported results for the second quarter and first six months of fiscal 2008.
Revenues for the quarter ended December 31, 2007, were $5.5 million. This compares with revenues of $3.7 million for the second quarter of fiscal 2007 and $3.6 million for the first quarter of fiscal 2008. Total disposable revenues were $2.6 million, a 44 percent increase over disposable revenues of $1.8 million in the second quarter a year ago.
The Company reported a net loss of $1.7 million, or $0.03 per share, in the second quarter of fiscal 2008, versus a loss of $2.0 million, or $0.04 per share, in the second quarter a year ago. At December 31, 2007, ThermoGenesis had $30.5 million in cash, cash equivalents and short-term investments. Total cancellable backlog at the end of the second fiscal quarter was $3.9 million, a 50 percent increase over the $2.6 million in cancellable backlog a year ago.
"As we discussed in our January 10th update news release, the primary growth drivers during the quarter were increased AXP(TM) AutoXpress Platform (AXP) bag set shipments, improved BioArchive(R) System sales and growth in CryoSeal(R) FS System and disposable sales," noted Dr. William Osgood, the Company's Chief Executive Officer.
Osgood said the Company's results reflect its success in addressing AXP
bag set production quality. In addition, the Company shipped 8 BioArchive
devices during the quarter which compares to 3 devices shipped in the prior
year same quarter, bringing the total number of installed BioArchiv
|SOURCE ThermoGenesis Corp.|
Copyright©2008 PR Newswire.
All rights reserved